[
  {
    "ts": null,
    "headline": "Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025",
    "summary": "FOSTER CITY, Calif., October 19, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead’s leadership in advancing antiviral science and its ongoing efforts to bring forward innovative solutions for people and communit",
    "url": "https://finnhub.io/api/news?id=4f975da78deb92bda431695a546730ff1431f33820aacb7530011ee55fdaa1f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760877000,
      "headline": "Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025",
      "id": 137164516,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., October 19, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek, taking place October 19-22 in Atlanta, GA. Data from 34 presentations across HIV, respiratory viruses, viral hepatitis, and viruses of pandemic potential including six oral presentations underscore Gilead’s leadership in advancing antiviral science and its ongoing efforts to bring forward innovative solutions for people and communit",
      "url": "https://finnhub.io/api/news?id=4f975da78deb92bda431695a546730ff1431f33820aacb7530011ee55fdaa1f1"
    }
  },
  {
    "ts": null,
    "headline": "Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study",
    "summary": "FOSTER CITY, Calif., October 19, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Trodelvy® (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitors. These findings will be presented to",
    "url": "https://finnhub.io/api/news?id=38290fcafcf26e69398fe71f5221a8e47bfe2d357a6f46daefdfa3a800ef9d11",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760855400,
      "headline": "Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study",
      "id": 137164517,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., October 19, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today shared positive data from the Phase 3 ASCENT-03 study demonstrating a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) for Trodelvy® (sacituzumab govitecan-hziy) compared to chemotherapy as first-line treatment in patients with metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitors. These findings will be presented to",
      "url": "https://finnhub.io/api/news?id=38290fcafcf26e69398fe71f5221a8e47bfe2d357a6f46daefdfa3a800ef9d11"
    }
  }
]